Comparative Pharmacology
Head-to-head clinical analysis: GLUCOPHAGE XR versus GLUMETZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOPHAGE XR versus GLUMETZA.
GLUCOPHAGE XR vs GLUMETZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biguanide; decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Metformin hydrochloride, a biguanide, improves glucose tolerance in type 2 diabetes mellitus by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity (increasing peripheral glucose uptake and utilization).
Metformin XR: initial 500 mg orally once daily with evening meal, increase by 500 mg weekly; max 2000 mg per day (as XR, given once or divided twice daily).
Initial: 500 mg orally once daily with evening meal; increase by 500 mg weekly based on tolerability. Maximum: 2000 mg once daily with evening meal. Extended-release formulation.
None Documented
None Documented
Terminal elimination half-life: 17.6 hours (range 9.1–40.6 hours); clinical context: reflects slow absorption from extended-release matrix; accumulation occurs with renal impairment
6.2 hours (terminal) in healthy adults; prolonged in renal impairment (e.g., 18 hours in CrCl <30 mL/min)
Renal: 90% unchanged; fecal: minimal (<5%)
Renal (90% as unchanged drug); fecal (minor, <5%)
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic